A 48-year-old man with chronic kidney disease (eGFR 35 mL/min/1.73m²) and hypertension develops progressive left ventricular hypertrophy. His serum potassium is 4.8 mEq/L and creatinine is 2.1 mg/dL. Which agent is the preferred first-line choice to promote LVH regression while providing renal protection?

Explanation

## ARBs for LVH Regression in CKD **Key Point:** Angiotensin II receptor blockers (ARBs) like losartan are the preferred first-line agents for LVH regression in patients with chronic kidney disease because they provide both cardiac hypertrophy reversal and renal protection via glomerular hemodynamic reduction. ### Why ARBs Over ACE Inhibitors in This Scenario **Clinical Pearl:** While both ACE inhibitors and ARBs are equally effective for LVH regression, ARBs are often preferred in CKD patients because: 1. **No dry cough** — ARBs do not inhibit bradykinin metabolism, eliminating the 10–20% incidence of ACE inhibitor-induced cough 2. **Equivalent renal protection** — Both classes reduce intraglomerular pressure and proteinuria 3. **Better tolerability** — Higher compliance in long-term CKD management 4. **Angiotensin II escape** — ARBs directly block AT1 receptors, bypassing the tissue-level ACE escape phenomenon ### Mechanism of LVH Regression and Renal Protection ```mermaid flowchart TD A[Chronic Hypertension + CKD]:::outcome --> B[Angiotensin II overactivity]:::outcome B --> C[AT1 receptor activation]:::outcome C --> D{Tissue effects}:::decision D -->|Cardiac| E[Fibroblast proliferation<br/>Collagen deposition<br/>LVH]:::outcome D -->|Renal| F[Efferent arteriole<br/>vasoconstriction<br/>Glomerulosclerosis]:::outcome G[Losartan blocks AT1]:::action --> H[Reduced cardiac hypertrophy]:::action G --> I[Reduced glomerular pressure<br/>Proteinuria reduction]:::action H --> J[LVH regression]:::outcome I --> K[Slowed CKD progression]:::outcome ``` ### Comparative Drug Selection in CKD with LVH | Agent | LVH Regression | Renal Protection | CKD Suitability | Notes | | --- | --- | --- | --- | --- | | **Losartan (ARB)** | ★★★★★ | ★★★★★ | Excellent | Preferred; no cough; direct AT1 blockade | | **Lisinopril (ACE-I)** | ★★★★★ | ★★★★★ | Good | Excellent but 15% cough rate; monitor K⁺ | | **Amlodipine** | ★★★☆☆ | ★★☆☆☆ | Fair | Modest LVH regression; no renal protection | | **Atenolol** | ★★☆☆☆ | ★★☆☆☆ | Fair | Minimal LVH effect; contraindicated in CKD (metabolic complications) | | **Chlorthalidone** | ★☆☆☆☆ | ★☆☆☆☆ | Poor | Thiazide-like diuretic; worsens glucose/lipids; no LVH benefit | **High-Yield:** In CKD patients with hypertension and LVH, RAAS blockade (ACE-I or ARB) is mandatory. ARBs are often chosen over ACE-I for tolerability, but both are superior to calcium channel blockers, beta-blockers, or diuretics for this indication. **Mnemonic:** **RAAS in CKD** — Remember: **R**AS blockade (ACE-I or ARB) is **A**lways **A**dvised for **S**tructure protection (cardiac and renal) in CKD. **Warning:** Do not confuse ARB efficacy with ACE inhibitor efficacy — they are equivalent for LVH regression and renal protection, but ARBs have better tolerability in long-term CKD management due to absence of cough.